Anika Therapeutics, Inc. Restructuring Costs
Anika Therapeutics, Inc. (ANIK) reported Restructuring Costs of $2.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-07-29
- Anika Therapeutics, Inc. restructuring costs for the quarter ending 2026-06-30 was $0.00.
- Anika Therapeutics, Inc. restructuring costs for the quarter ending 2026-03-31 was $2.30M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $2.30M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $2.30M 10-Q · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |